Tumor specific delivery and therapy mediate by integrin β6-target immunoliposomes for β6-siRNA in colon carcinoma

Oncotarget. 2016 Dec 20;7(51):85163-85175. doi: 10.18632/oncotarget.13209.

Abstract

Adjuvant chemotherapy does not achieve the desired therapeutic efficacy in colon cancer as a result of the deficient reaction. Gene therapy using small interfering RNAs (siRNAs) delivered by target delivering system represents a potent and specific strategy in tumor therapy. Integrinβ6 is exclusively expressed in malignant colonic epithelia, associated with the progression, metastasis, and chemotherapeutic resistance of colon cancer. Accordingly, designing an efficient and targeted delivery system for β6-siRNA could be a potential approach to improve therapeutic efficacy of colon cancer. Here, we designed the Integrinβ6 target immunoliposomes for highly efficient and selective delivery of β6-siRNA in colon cancer, which consequently resulted in greatly growth suppression, invasion and metastasis of colon cancer cells. Moreover, it was able to greatly inhibit the tumor growing in vivo.

Keywords: colon carcinoma; immunoliposomes; integrinβ6; siRNA; target therapy.

MeSH terms

  • Animals
  • Cell Growth Processes
  • Cell Line, Tumor
  • Cell Movement
  • Colon / pathology*
  • Colonic Neoplasms / genetics
  • Colonic Neoplasms / therapy*
  • Drug Delivery Systems
  • Female
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Integrin beta Chains / genetics*
  • Intestinal Mucosa / physiology*
  • Liposomes / chemical synthesis
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Neoplasm Metastasis
  • RNA, Small Interfering / chemical synthesis
  • RNA, Small Interfering / genetics*
  • Tumor Burden
  • Xenograft Model Antitumor Assays

Substances

  • Integrin beta Chains
  • Liposomes
  • RNA, Small Interfering
  • integrin beta6